Association in 2004. The histopathology examination and TTC staining agree with the AMI diagnosis too. The experiment of rabbits in IR group was in accordance with the recanalisation criteria of IRCA recommended by the Chinese J Cardiol editorial committee in 1991. The injection of Evan’s Blue was in coincidence with the recanalisation of IRCA too.

Conclusions AMI-reperfusion rabbit models can be successfully established by the application of this method. It has proved to be very effective.

**e0237** EXTRACELLULAR MATRIX ISOLATED FROM MYOCARDIAL TISSUE SUPPORTS THE CARDIOMYOCYTE DIFFERENTIATION OF EMBRYONIC STEM CELLS

doi:10.1136/hrt.2010.208967.237

Ou Dongbo, Zheng Qiangsun, He Yong, Wang Zikuan. Department of Cardiology, Tangdu Hospital Fourth Military Medical University, Xi’an, China

**Objective** Embryonic stem cells (ESCs) represent an extremely promising cell source for tissue-engineered myocardial tissue. But the role of extracellular matrix in control and guidance of ESCs differentiation and commitment into complex and viable three-dimensional (3D) myocardial tissue is still poorly understood. The purpose of this study was to identify and functionally characterise survive and differentiation of ESCs in 3D extracellular matrices isolated from myocardial tissues.

**Methods** Undifferentiated ESCs were cultured as previously described. Native myocardial tissues isolated from hearts of adult rabbit were treated with trypsin-EDTA and NaOH to remove cell components to gain acellular matrices. The acellularization of myocardial tissues was documented by haematoxylin-eosin staining (HE staining). Then ESCs were seeded onto the acellular matrices. Cell density and distribution were assessed by HE staining, cardiac transcription factors such as Nkx2.5, and atrial natriuretic factor (ANF) were evaluated by RT-PCR, and cardiac markers such as α-actinin, troponin I, and connexin43 were evaluated by immunocytochemistry. Ultrastructural analysis was examined under a transmission electron microscope.

**Results** The acellular matrices were incompletely covered by cells at 1 week, and the intimitis of matrices were densely repopulated by cells at 2 weeks post seeding, indicating the rapid growth and expansion of these cells in the extracellular matrices and the formation of live constructs. Cardiac transcription factors GATA4 and NKX2.5 began to express on day 10, but the expression of ANF was detected on day 12. The constructs were positively immunostained with α-actinin, troponin I, and connexin43 at 2 weeks post seeding. Ultrastructural analysis indicates that cells in constructs exhibited the morphological features including sarcomeres, abundant glycogen and mitochondria and nascent junctional complexes.

**Conclusions** These results indicate that extracellular matrices have the potential to promote the differentiation of embryonic stem cells into cardiomyocytes. Such cell differentiation with extracellular matrices may be useful in forming tissue-engineered myocardial tissue to repair specific damaged hearts.

**e0238** EFFECTS OF COMBINED ATORVASTATIN/COENZYME Q10 ON MYOCARDIAL FIBROSIS AND MALONDIALDEHYDE (MDA) AND SUPEROXIDE DISMUTASE (SOD) IN RAT OF HEART FAILURE

doi:10.1136/hrt.2010.208967.238

Zhao Dongming, Yang Ping. 1Affiliated Hospital of Beihua University; 2China-japan Union Hospital of Jilin University

**Objective** To observe the effects of Combined Atorvastatin/Coenzyme Q10 on myocardial fibrosis and MDA and SOD in Rat of heart failure, to explore the protective effect of Combined Atorvastatin/Coenzyme Q10 on the heart of the rat.

**Methods** Female Wister rats were subjected to the ligation of the anterior descending branch of the left coronary artery or sham operation during halothane anaesthesia. The rat heart failure models were established after 6 weeks. These rats were divided into four groups (n=6 each group): Sham operated group; model group; model group-atorvastatin, Rats in this treatment group were administrated by gastric perfusion of atorvastatin (10 mg/kg/day); model group-atorvastatin-Coenzyme Q10. Rats in this treatment group were administrated by gastric perfusion of atorvastatin (10 mg/kg/day) and Coenzyme Q10 (50 mg/kg/day). All treatment regimens were initiated 6 weeks after surgery and continued for 5 weeks. After Masson stain, myocardial fibrosis of these rats were observed by light microscope. The activity of serum SOD and the content of serum MDA were detected by biochemical methods.

**Results** Compared with that in model group, myocardial fibrosis level and MDA content was decreased in model group-atorvastatin (p<0.01). At the same time, the activity of SOD was increased (p<0.01). Compared with that in model group-atorvastatin, myocardial fibrosis level and MDA content was decreased in model group-atorvastatin-Coenzyme Q10 (p<0.05). At the same time, the activity of SOD was increased (p<0.05).

**Conclusion** Compared with atorvastatin, Combined atorvastatin/ coenzyme Q10 could protect the myocardium further, and MAD and SOD maybe were involved in this process.

**e0239** N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-proBNP): A POTENTIAL DIAGNOSTIC BIOMARKER FOR PREDICTING CARDIAC DYSFUNCTION IN PATIENTS WITH LIVER DISEASES

doi:10.1136/hrt.2010.208967.239

1Wang Ling, 2Gang Jiabo, 2Chang Yiben, 2Li Tong, 2Matsumori Akira, 2Zhuang Hui. 1Peking University Health Science Center, 2Department of Cardiovascular Medicine Kyoto University Japan

**Background** NT-proBNP has emerged as a powerful diagnostic and prognostic biomarker in heart disease. Studies showed that NT-proBNP is a sensitive biomarker for identifying patients with heart failure caused by hepatitis C virus (HCV) related myocarditis. The aim of this study was to investigate the relationship between the elevated concentration of NT-proBNP and liver diseases.

**Methods** 223 serum samples from blood donors were collected as a control group, and 644 samples were obtained from patients infected by hepatitis viruses including 493 HBV (364 chronic hepatitis B, 86 hepatocellular carcinoma and 43 liver cirrhosis) and 151 HCV. All samples were assayed with an Elecsys immunoassay analyser for NT-proBNP concentration.

**Results** The mean concentration of NT-proBNP in the control group was 21.77±15.56 pg/ml which showed no significant variation with age or gender. Both the mean value and the rate of abnormality of NT-proBNP were significantly higher for the HBV and HCV infected groups as compared to the control group. The mean NT-proBNP value (380.24 pg/ml) and abnormality rate (58.41%) in the HCV group were higher than that of HBV group. For samples from patients with HBV related hepatic disease/pathology, the mean NT-proBNP value (517.19 pg/ml) and abnormality rate (58.14%) were the highest in the liver cirrhosis group.

**Conclusion** The elevation of NT-proBNP in patients with progressed liver disease in this study suggested the presence of cardiac dysfunction.